Aligos Therapeutics, Inc.
ALGSNext catalyst
ALG-000184
Chronic Hepatitis B Infection
Get an email about ALGS's next catalysts
Track Aligos Therapeutics (ALGS) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 1 past
ALG-000184 Phase 2 Est. Readout (B-SUPREME)
Primary completion for ALG-000184 trial (NCT06963710) in Chronic Hepatitis B Infection
SourceMarket Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ALG-000184 | Phase 2 | Chronic Hepatitis B Infection | - | - |
ALG-055009 | Phase 2 | NASH | - | - |
Frequently asked questions
What is in Aligos Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Aligos Therapeutics, Inc.'s (ALGS) pipeline across Phase 2. Its lead program is ALG-000184 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Aligos Therapeutics, Inc.'s next FDA catalyst?→
Aligos Therapeutics, Inc.'s (ALGS) next tracked catalyst is a Phase 2 readout expected March 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ALGS biotech catalysts?→
Add ALGS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Aligos Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.